Scalable Testing: Enabling labs to meet the demands of the COVID-19 pandemic

The SARS-CoV-2 coronavirus has created an enormous challenge for laboratories and communities worldwide. To address the crisis presented by COVID-19, labs need an accurate testing method capable of cost-effectively processing large numbers of samples.

The MassARRAY^® SARS-CoV-2 Panel from Agena Bioscience^® enables high-throughput, low-cost detection of COVID-19 caused by SARS-CoV-2 infection. The single-well, multiplexed assay targets 5 highly conserved regions of the viral genome, providing high accuracy and low limit of detection.

Available Now
The MassARRAY SARS-CoV-2 Panel has received Emergency Use Authorization (EUA) for in vitro diagnostic use in the U.S. from the FDA. The MassARRAY SARS-CoV-2 Panel is CE-IVD marked and intended for in vitro diagnostic use in Europe. For other regions, please visit our Research Use Only Panel.